31 October 2022
ECO Animal Health Group PLC
BLOCK LISTING RETURN
Date: 31 October 2022
| Name of applicant: | ECO Animal Health Group plc | |||
| Name of scheme: | Executive Share Option Scheme and Unapproved Share Option Scheme | |||
| Number and class of securities originally listed and the date of admission: | 1,500,000 ordinary shares of 5 pence each on 20 July 2017 | |||
| Period of return: | From: | 29 April 2022 | To: | 31 October 2022 |
| Balance of unallotted securities under scheme(s) from previous return: | 375,505 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period: | 0 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 375,505
| |||
| | | | | |
For further information, please contact:
|
ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
|
|
| IFC Advisory Graham Herring Zach Cohen
| 020 3934 6630
|
| Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas
| 020 7496 3000 |
| Investec (Joint Broker) Gary Clarence Brough Ransom Carlo Spingardi
Peel Hunt LLP (Joint Broker) Dr Christopher Golden James Steel | 020 7597 5970
020 7418 8900 |
| Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
